Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > also 🚩
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(162)
•••
Comment by Benedictuson Jan 30, 2024 12:46am
128 Views
Post# 35851961

RE:RE:RE:RE:RE:also 🚩

RE:RE:RE:RE:RE:also 🚩
MrMugsy wrote:

Benedictus - from AGM, we know there is confidence on a few fronts.  We also know there are discussions underway.  No details, just that the company is doing what they can in advance.

and ...

with a mountain of OTENA data behind us, we know where we stand with amorphous.  In God's hands now w.r.t. financing.

I wouldn't read much into the last presentation or any general presentation - just not going to move the needle.  They are slow intros for small groups of people.

That being said - something else and something big would be required to make the warrants exciting by February 15th.

In the end, doesn't matter.  Not worth the worry.  We're heading into P2 with a whole understanding of how excitement and nervous wonder cause retail investors to ride that share price coaster one more time.  

This time, money well spent to reposition - derisk and position for much, much more.  Love this game !!!!


Thanks Mugs, appreciate your perspective as always. Should be an exciting year!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities